Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Placebo-controlled Study of Rituximab in Patients with Psychosis And/or Obsessive Compulsive Disorder, with an Indication of Immune System Involvement

NCT04323566 is registered in ClinicalTrials.gov with Uppsala University Hospital as lead sponsor.

NCT NCT04323566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04323566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Placebo-controlled Study of Rituximab in Patients with Psychosis And/or Obsessive Compulsive Disorder, with an Indication of Immune System Involvement
Lead sponsor
Uppsala University Hospital
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
May 1, 2022
Completion date
December 1, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brief psychotic disorder, delusional disorder, obsessive-compulsive behavior, obsessive-compulsive disorder, other psychoses, schizo affective disorder, schizophrenia, unspecified psychosis